Alefacept for the treatment of psoriasis and other dermatologic diseases

Dermatologic Therapy

Volumn 20, Issue 4, 2007, Pages 270-276

  Strober, Bruce E ^a   Menon, Kavita ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alefacept; Biologic therapy; Psoriasis; Psoriatic arthritis

Indexed keywords

ALEFACEPT; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CLOBETASOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; IMMUNOGLOBULIN G1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; METHOTREXATE;

APOPTOSIS; ASPERGILLOSIS; CELL FUNCTION; CHILL; CLINICAL TRIAL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; HEMORRHAGIC CYSTITIS; HODGKIN DISEASE; HUMAN; IMMUNOREACTIVITY; INFLUENZA; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MEMORY T LYMPHOCYTE; MONOTHERAPY; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PATHOPHYSIOLOGY; PHOTOTHERAPY; PNEUMONIA; PSORIASIS; QUALITY OF LIFE; REMISSION; REVIEW; RHINOPHARYNGITIS; SINUSITIS; SKIN DISEASE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION;

DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; PSORIASIS; RECOMBINANT FUSION PROTEINS; SKIN DISEASES;

EID: 35648977687     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00140.x     Document Type: Review

References (41)

1. Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 2002 : 29 : 415 426.
2. Amevive [package insert]. Cambridge (MA) Biogen, Inc, 2003.
3. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 : 345 : 248 245.
4. Krueger GG, Papp KA, Stough DB, et al. For the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002 : 47 : 821 833.
5. Lebwohl M, Christophers E, Langley RG, et al. For the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003 : 139 : 719 727.
6. Gribetz CH, Blum R, Brady C, et al. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005 : 53 : 73 75.
7. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003 : 2 : 624 628.
8. Menter A, Cather JC, Baker D, et al. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2005 : 54 : 61 63.
9. Langley RG, Cherman AM, Gupta AK. Alefacept: an expert review concerning the treatment of psoriasis. Expert Opin Pharmacother 2005 : 6 : 2327 2333.
10. Scheinfeld N. Alefacept: a safety profile. Expert Opin Drug Safety 2005 : 4 : 975 985.
11. Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg 2004 : 8 : 14 19.
12. Chamian F, Lowes M, Lin S, et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005 : 102 : 2075 2080.
13. Sweetser M, Ticho B, Swan S. Subcutaneous administration of alefacept is bioequivalent to intramuscular administration: Results of a randomized, open-label, crossover study in healthy volunteers. Poster presented at the American Academy of Dermatology meeting. San Francisco, CA, USA. J Am Acad Dermatol 2006 : 54 (3 Suppl. 1 P2907.
14. Strober B. Successful treatment of plaque psoriasis with self-administered subcutaneous alefacept. Arch Dermatol 2005 : 141 : 1602.
15. Leonardi C, Strober B. On multiple courses of alefacept. J Am Acad Dermatol 2006 : 55 : 916 917.
16. Mease P, Gladman D, Keystone E, Group AiPAS. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006 : 54 : 1638 1645.
17. Gordon K, Krueger GG, van de Kerkhof P, Gottlieb A. Efficacy and safety of multiple courses of alefacept in combination with other psoriasis therapies. Poster presented at the American Academy of Dermatology meeting. New Orleans, LA, USA. J Am Acad Dermatol 2005 : 52 (3 Suppl. 1 P183.
18. Ortonne JP, Khemis A, Koo J, Choi J. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005 : 19 : 556 563.
19. Koo J, Bagel J, Sweetser M, Ticho B. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol 2006 : 5 : 623 628.
20. Feldman S, McCarty A, Pearce D, Fleischer A. Safety and efficacy of an extended course of high-dose (30 mg) alefacept in combination with UVB. Poster presented at the American Academy of Dermatology meeting. San Francisco, CA, USA. J Am Acad Dermatol 2006 : 54 (3 Suppl. 1 AB224.
21. Gold M, Goldman M. Efficacy and safety of alefacept plus photodynamic therapy in chronic plaque psoriasis. Poster presented at the American Academy of Dermatology meeting. New Orleans, LA, USA. J Am Acad Dermatol 2005 : 52 (3 Suppl. 1 P182.
22. Moore A, Wright E, Slay D, Moore T. Alefacept, acitretin, and narrowband UVB combination therapy for plaque-type psoriasis allows faster withdrawal and shortens onset of action. Poster presented at the American Academy of Dermatology meeting. San Francisco, CA, USA. J Am Acad Dermatol 2006 : 54 (3 Suppl. 1 AB11.
23. van Duijnhoven M, Vissers WH, Pasch M, van de Kerkhof PC. Effects of alefacept and alefacept in combination with calcipotriol on epidermal cell populations in psoriatic lestions. Poster presented at the American Academy of Dermatology meetingy. New Orleans, LA, USA. J Am Acad Dermatol 2005 : 52 (3 Suppl. 1 P182.
24. Hodulik SG, A ZJ. Combination therapy with acitretin for psoriasis. J Dermatol Treatment 2006 : 17 : 108 111.
25. van Duijnhoven M, de Jong E, Gerritsen W, Pasch M, van de Kerkhof P. Alefacept modifies long-term disease severity and improves the response to other treatments. Eur J Dermatol, 2005 : 15 : 366 373.
26. Bovenschen H, Gerritsen W, van Rens D, Seyger M, de Jong E, van de Kerkhof P. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. Arch Dermatol Res 2007 : 298 : 457 463.
27. Krell JM. Use of alefacept and etanercept in three patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol 2005 : 54 : 1099 1102.
28. Yeung-Yue K, Aronson PJ, Murakawa GJ. Clinical improvement of palmoplantar pustular psoriasis with alefacept. Poster presented at the American Academy of Dermatology meeting. New Orleans, LA, USA. Journal of the American Academy of Dermatology (2005 52 (3 Suppl. 1 P179.
29. Fivenson D, Mathes B. Treatment of generalized lichen planus with alefacept. Archives of Dermatology 2006 : 142 : 151 152.
30. Heffernan M, Hurley M, Martin K, et al. Alefacept for alopecia areata. Archives of Dermatology 2005 : 141 : 1513 1516.
31. Toor A, Stiff P, Nickoloff B, et al. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. Journal of Dermatological Treatment 2007 : 18 : 13 18.
32. Shapira M, Resnick I, Bitan M, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 2005 : 36 : 1097 1101.
33. Thielen A, Kuenzli S, Saurat J-H. Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature. Dermatology 2005 : 211 : 209 217.
34. Ticho B, Bozic C, Cather J. A simple algorithm for reduced lymphocyte monitoring with alefacept therapy. Poster presented at the American Academy of Dermatology meeting. New Orleans, LA, USA. Journal of the American Academy of Dermatology (2005 52 (3 Suppl. 1): P174.
35. Goffe B, Papp KA, Gratton D, et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clinical Therapeutics 2005 : 27 : 1912 1921.
36. Gottlieb AB, Casale TB, Frankel E, et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept : Results of a randomized study. Journal of the American Academy of Dermatology 2003 : 49 : 816 825.
37. Menter MA, Cather JC, Abramovits W. Tuberculosis testing and the use of biologic therapies for the treatment of Psoriasis. Poster presented at the American Academy of Dermatology meeting. Washington, DC, USA. Journal of the American Academy of Dermatology (2004 50 (3 Suppl. 1 P176.
38. Thaci D, Patzold S, Kaufmann R, Boehncke W. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol 2005 : 152 : 1048 1050.
39. Flammiger A, Maibach H. Drug Dosage in the Elderly: Dermatologic Drugs. Drugs and Aging 2006 : 23 : 203 215.
40. Gottlieb AB, Boehncke W-H, Darif M. Safety and Efficacy of Alefacept in Elderly Patients and Other Special Populations. Journal of Drugs in Dermatology 2005 : 4 : 718 724.
41. Nelson A, Pearce D, Fleischer A, et al. New treatments for psoriasis: which biologic is best? Journal of Dermatological Treatment 2006 : 17 : 96 107.